These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32253275)

  • 1. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
    van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
    Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
    JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
    PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
    An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
    Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
    Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
    J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
    Petrykiv SI; Laverman GD; Persson F; Vogt L; Rossing P; de Borst MH; Gansevoort RT; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Nov; 12(11):1804-1813. PubMed ID: 29021336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
    Susantitaphong P; Sewaralthahab K; Balk EM; Eiam-ong S; Madias NE; Jaber BL
    Am J Hypertens; 2013 Mar; 26(3):424-41. PubMed ID: 23382494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
    Chan EY; Ma AL; Tullus K
    Pediatr Nephrol; 2021 Jul; 36(7):1751-1764. PubMed ID: 33057769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.
    Weir MR; Lakkis JI; Jaar B; Rocco MV; Choi MJ; Kramer HJ; Ku E
    Am J Kidney Dis; 2018 Dec; 72(6):873-884. PubMed ID: 30201547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
    Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
    Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Qiao Y; Shin JI; Sang Y; Inker LA; Secora A; Luo S; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    Mayo Clin Proc; 2019 Nov; 94(11):2220-2229. PubMed ID: 31619367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.
    Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A
    BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
    Jiménez-Marrero S; Cainzos-Achirica M; Monterde D; Vela E; Enjuanes C; Yun S; Garay A; Moliner P; Corbella M; Jovells-Vaqué S; Alcoberro L; Pons-Riverola A; Ramos-Polo R; Morillas H; Gómez-Hospital JA; Comin-Colet J
    Eur J Intern Med; 2024 Jul; 125():89-97. PubMed ID: 38548513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.